Trabecular Micro-Bypass Outcomes After Routine Cataract Surgery
Narrative Responses:
Purpose
To evaluate the results of the iStent implanted at time of routine cataract surgery in patients diagnosed with chronic open angle glaucoma.
Methods
Retrospective chart review of patients who underwent uneventful phacoemulsification and iStent Trabecular Micro Bypass implantation between August 1, 2012 and January 30, 2013. All patients had one iStent implanted. Preoperative and at least 3-week postoperative intraocular pressure (IOP), number of medications used, and iStent intra and postoperative complications were evaluated.
Results
Thirty-three eyes of 21 patients have been analyzed. Mean age, 72.3 ±7.0 years. 48% were females. Mean preoperative IOP, 16.9 ± 5.0 mmHg; 86% (18), 9% (2), and 5% (1) were using 1, 2, and 3 medications, respectively. Mean IOP was 18.8 ±6.8 and 16.1 ±5.1 mmHg on POD#1 and POD#21, respectively. Three eyes of 3 patients who had unilateral implantation of the iStent were still on medication. When excluding these 3 eyes, the mean IOP was 15.8 ±5.5 mmHg on POD#21. Patients using 2 and 3 medications prior to surgery werenot using any medication postoperatively. No complications were seen.
Conclusion
iStent Trabecular Micro-Bypass seems to be a safe alternative to patients with chronic open glaucoma undergoing routine cataract surgery. The use of iStent reduced the IOP to baseline levels without using any anti-glaucoma medication.